Hematopoietic stem cell transplantation for non-Hodgkin lymphoma

Research output: Contribution to journalReview articlepeer-review

20 Scopus citations


Up-front rituximab-based chemotherapy has improved outcomes in non-Hodgkin lymphoma (NHL); refractory or relapsed NHL still accounts for approximately 18,000 deaths in the United States. Autologous hematopoietic stem cell transplantation (SCT) can improve survival in primary refractory or relapsed aggressive NHL and mantle cell lymphoma and in relapsed follicular or peripheral T-cell lymphoma. Autologous SCT as a consolidation therapy after first complete or partial remission in high-risk aggressive NHL, mantle cell lymphoma, and peripheral T-cell lymphoma may improve progression-free survival. Allogeneic SCT offers a lower relapse rate but a higher nonrelapse mortality resulting in overall survival similar to autologous SCT.

Original languageEnglish (US)
Pages (from-to)1073-1095
Number of pages23
JournalHematology/Oncology Clinics of North America
Issue number6
StatePublished - Dec 1 2014


  • Allogeneic hematopoietic stem cell transplantation
  • Autologous hematopoietic stem cell transplantation
  • Diffuse large B-cell lymphoma
  • Follicular lymphoma
  • Mantle cell lymphoma
  • Non-Hodgkin lymphoma
  • Peripheral T-cell lymphoma

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Hematopoietic stem cell transplantation for non-Hodgkin lymphoma'. Together they form a unique fingerprint.

Cite this